180 related articles for article (PubMed ID: 25774058)
1. Prednisone in Uric Acid Lowering in Symptomatic Heart Failure Patients with Hyperuricemia -- The PUSH-PATH3 Study.
Meng H; Liu G; Zhai J; Zhen Y; Zhao Q; Zheng M; Ma G; Wang L; Tian L; Ji L; Duan L; Li L; Liu K; Liu C
J Rheumatol; 2015 May; 42(5):866-9. PubMed ID: 25774058
[TBL] [Abstract][Full Text] [Related]
2. Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study.
Liu C; Zhao Q; Zhen Y; Gao Y; Tian L; Wang L; Ji L; Liu G; Ji Z; Liu K
Can J Cardiol; 2013 Sep; 29(9):1048-54. PubMed ID: 23395281
[TBL] [Abstract][Full Text] [Related]
3. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
4. High-dose prednisone in patients with heart failure and hyperuricemia: friend and foe?
de Denus S; Rouleau JL
Can J Cardiol; 2013 Sep; 29(9):1021-3. PubMed ID: 23535276
[No Abstract] [Full Text] [Related]
5. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
[TBL] [Abstract][Full Text] [Related]
6. Hypouricemic effects of prednisone and allopurinol: an uneven playing field?
Kannangara DR; Graham GG; Williams KM; Day RO
Can J Cardiol; 2014 Mar; 30(3):376.e1. PubMed ID: 23831009
[No Abstract] [Full Text] [Related]
7. Reply to Day et al.--hypouricemic effect of prednisone in heart failure: possible mechanisms.
Liu C; Liu K
Can J Cardiol; 2014 Mar; 30(3):376.e3. PubMed ID: 23831010
[No Abstract] [Full Text] [Related]
8. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia.
Levy GD; Rashid N; Niu F; Cheetham TC
J Rheumatol; 2014 May; 41(5):955-62. PubMed ID: 24692523
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
10. Prednisone for cardiac failure in patients with hypertension.
Day RO
J Rheumatol; 2015 May; 42(5):739-40. PubMed ID: 25934877
[No Abstract] [Full Text] [Related]
11. A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Perez-Ruiz F; Herrero-Beites AM; Carmona L
Arthritis Rheum; 2011 Dec; 63(12):4002-6. PubMed ID: 21898351
[TBL] [Abstract][Full Text] [Related]
12. Urate-lowering therapy in patients with hyperuricemia and heart failure: A retrospective cohort study using the UK Clinical Practice Research Datalink.
Kiddle SJ; Sundell KA; Perl S; Nolan S; Bjursell M
Clin Cardiol; 2024 Jun; 47(6):e24297. PubMed ID: 38873862
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
14. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
15. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
Dalbeth N; Kumar S; Stamp L; Gow P
J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
[TBL] [Abstract][Full Text] [Related]
17. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
18. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Whelton A; MacDonald PA; Chefo S; Gunawardhana L
Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
20. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]